• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    1/22/24 4:31:12 PM ET
    $ACET
    $ADAG
    $BBLG
    $BCLI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACET alert in real time by email

    Gainers

    • Cadrenal Therapeutics (NASDAQ:CVKD) shares moved upwards by 8.5% to $1.15 during Monday's after-market session. The market value of their outstanding shares is at $14.9 million.
    • vTv Therapeutics (NASDAQ:VTVT) shares moved upwards by 6.98% to $9.95. The company's market cap stands at $20.2 million.
    • Passage Bio (NASDAQ:PASG) stock increased by 6.94% to $0.97. The market value of their outstanding shares is at $53.1 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares moved upwards by 6.08% to $2.44. The market value of their outstanding shares is at $1.6 million.
    • Brainstorm Cell (NASDAQ:BCLI) stock increased by 5.76% to $0.31. The market value of their outstanding shares is at $15.1 million.
    • Kazia Therapeutics (NASDAQ:KZIA) stock rose 5.62% to $0.37. The market value of their outstanding shares is at $9.7 million.

    Losers

    • Adicet Bio (NASDAQ:ACET) shares decreased by 22.1% to $1.94 during Monday's after-market session. The company's market cap stands at $83.7 million.
    • Adagene (NASDAQ:ADAG) stock fell 13.34% to $2.6. The company's market cap stands at $113.9 million.
    • Bone Biologics (NASDAQ:BBLG) shares declined by 6.9% to $3.51. The company's market cap stands at $1.8 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) shares fell 5.96% to $0.79.
    • Cabaletta Bio (NASDAQ:CABA) shares declined by 5.87% to $19.27. The company's market cap stands at $825.7 million.
    • DocGo (NASDAQ:DCGO) shares fell 5.49% to $3.25. The company's market cap stands at $337.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACET alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACET
    $ADAG
    $BBLG
    $BCLI

    CompanyDatePrice TargetRatingAnalyst
    vTv Therapeutics Inc.
    $VTVT
    3/12/2026$44.00Outperform
    Evercore ISI
    Passage Bio Inc.
    $PASG
    2/10/2026$21.00Buy
    Chardan Capital Markets
    vTv Therapeutics Inc.
    $VTVT
    1/23/2026$58.00Buy
    Roth Capital
    vTv Therapeutics Inc.
    $VTVT
    1/5/2026$67.00Buy
    TD Cowen
    Adagene Inc.
    $ADAG
    11/24/2025$9.00Buy
    Guggenheim
    vTv Therapeutics Inc.
    $VTVT
    11/19/2025$40.00Buy
    BTIG Research
    Cabaletta Bio Inc.
    $CABA
    10/10/2025$14.00Buy
    Jefferies
    Adagene Inc.
    $ADAG
    8/6/2025$7.00Outperform
    Leerink Partners
    More analyst ratings

    $ACET
    $ADAG
    $BBLG
    $BCLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on vTv Therapeutics with a new price target

    Evercore ISI initiated coverage of vTv Therapeutics with a rating of Outperform and set a new price target of $44.00

    3/12/26 8:55:45 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets resumed coverage on Passage BIO with a new price target

    Chardan Capital Markets resumed coverage of Passage BIO with a rating of Buy and set a new price target of $21.00

    2/10/26 6:56:48 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Roth Capital initiated coverage on vTv Therapeutics with a new price target

    Roth Capital initiated coverage of vTv Therapeutics with a rating of Buy and set a new price target of $58.00

    1/23/26 8:21:38 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    $ADAG
    $BBLG
    $BCLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Chang David J. bought $19,888 worth of shares (8,800 units at $2.26) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:58 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President, Science & Tech. Binder Gwendolyn bought $24,763 worth of shares (11,312 units at $2.19), increasing direct ownership by 57% to 31,312 units (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:30 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Tomasello Shawn bought $50,322 worth of shares (22,725 units at $2.21) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:55:49 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACET
    $ADAG
    $BBLG
    $BCLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ethisphere Names DocGo as One of the 2026 World's Most Ethical Companies®

    20th annual recognition honors organizations committed to business integrity through robust ethics, compliance, and governance programs DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled medical transportation and mobile health services, announced today that it has been recognized as one of the 2026 World's Most Ethical Companies® by Ethisphere, a global leader in defining and advancing the standards of ethical business practices. This is DocGo's first time receiving this honor, and the Company is one of only four honorees in the healthcare providers and services category. In 2026, 138 honorees were recognized, spanning 17 countries and 40 indu

    3/18/26 7:35:00 AM ET
    $DCGO
    Medical/Nursing Services
    Health Care

    Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

    SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that muzastotug will be highlighted in two poster presentations at this year's AACR Meeting, taking place April 17-22 in San Diego, CA. The following abstracts have been selected for presentation at AACR 2026: Title: Ph1b evaluation of ADG126 (muzastotug, an anti-CTLA-4 masking antibody) pembrolizumab (Pembro) IO doublet in combination with fruquintinib (Fruq) in advanced and metastatic microsatellite stable colorectal cancerSession Title: Phase I Clinical Trials in Pr

    3/17/26 4:35:00 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DocGo Announces Fourth Quarter and Full Year 2025 Results

    Company Raises 2026 Revenue and Adjusted EBITDA Guidance due to Customer Expansions, Improved EMS Hiring Rates and Efficiency Initiatives Company Has Initiated a Formal Process to Explore Strategic Alternatives to Maximize Shareholder Value Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health and medical transportation services, today announced financial and operating results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights Total revenue for the fourth quarter of 2025 was $74.9 million, compared t

    3/16/26 4:05:00 PM ET
    $DCGO
    Medical/Nursing Services
    Health Care

    $ACET
    $ADAG
    $BBLG
    $BCLI
    SEC Filings

    View All

    SEC Form 424B3 filed by Kazia Therapeutics Limited

    424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

    3/19/26 5:19:24 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Kazia Therapeutics Limited

    424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

    3/19/26 5:17:11 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Kazia Therapeutics Limited

    424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

    3/19/26 5:14:01 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    $ADAG
    $BBLG
    $BCLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Coffey Steven R. S.

    3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)

    3/18/26 7:18:21 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Friend John E. Ii

    3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)

    3/18/26 6:35:38 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Simpson Jeremy

    3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)

    3/18/26 6:32:35 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    $ADAG
    $BBLG
    $BCLI
    Leadership Updates

    Live Leadership Updates

    View All

    vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026  Strengthened balance sheet provides funding runway well past the anticipated CATT1 Phase 3 topline readout HIGH POINT, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes ("T1D"), today reported financial results for the fourth quarter and full year ended December 31, 2025, and pro

    3/10/26 4:01:00 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    $ADAG
    $BBLG
    $BCLI
    Financials

    Live finance-specific insights

    View All

    DocGo Announces Fourth Quarter and Full Year 2025 Results

    Company Raises 2026 Revenue and Adjusted EBITDA Guidance due to Customer Expansions, Improved EMS Hiring Rates and Efficiency Initiatives Company Has Initiated a Formal Process to Explore Strategic Alternatives to Maximize Shareholder Value Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health and medical transportation services, today announced financial and operating results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights Total revenue for the fourth quarter of 2025 was $74.9 million, compared t

    3/16/26 4:05:00 PM ET
    $DCGO
    Medical/Nursing Services
    Health Care

    DocGo to Announce Fourth Quarter and Full Year 2025 Results on Monday, March 16, 2026

    Management to host conference call and webcast at 5:00 p.m. ET on that day DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled medical transportation and mobile health services, announced today that the Company will release its financial results for the fourth quarter and full year ended December 31, 2025, after the markets close on Monday, March 16, 2025. Management will also host a conference call to discuss these results and its outlook for 2026 at 5:00 p.m. ET on that day. Conference call and webcast details: Monday, March 16, 2026 5:00 p.m. ET 1-800-717-1738 (U.S.) 1-646-307-1865 (international) Conference ID: 74028 To access the Call m

    3/2/26 7:35:00 AM ET
    $DCGO
    Medical/Nursing Services
    Health Care

    Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

    Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds.Orphan Drug and Fast Track designations from the FDA PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics ("Veralox"). The acquisition immediately strengthens Cadren

    12/11/25 8:05:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    $ADAG
    $BBLG
    $BCLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/6/24 4:05:57 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/5/24 4:50:19 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/5/24 3:36:55 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care